___

• 1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377–385.
• 2. Kundakci N, Türsen U, Babiker MO, Gürgey E. The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients. Int J Dermatol 2002; 41: 220–224.
• 3. Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol 2007; 25: 606–615.
• 4. van de Kerkhof PCM. The evolution of psoriatic lesion. Br J Dermatol 2007; 157: 4–15.
• 5. Brooks GF, Carroll KC, Butel JS, Morse SA, Mietzner TA. In: Weitz M, Lebowitz H, editors. Jawetz, Melnick & Adelberg’s Medical Microbiology. 25th ed. New York, NY, USA: McGraw- Hill; 2013. pp 199–206.
• 6. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 520–532.
• 7. Holmes A, Ganner M, McGuane S, Pitt TL, Cookson BD, Kearns AM. Staphylococcus aureus isolates carrying Panton- Valentine leucocidin genes in England and Wales: frequency, characterization, and association with clinical disease. J Clin Microbiol 2005; 43: 2384–2390.
• 8. Foster TJ, Höök M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol 1998; 6: 484–488.
• 9. Speziale P, Pietrocola G, Rindi S, Provenzano M, Provenza G, Di Poto A, Visai L, Arciola CR. Structural and functional role of Staphylococcus aureus surface components recognizing adhesive matrix molecules of the host. Future Microbiol 2009; 4: 1337–1352.
• 10. Marraffini LA, Dedent AC, Schneewind O. Sortases and the art of anchoring proteins to the envelopes of gram-positive bacteria. Microbiol Mol Biol Rev 2006; 70: 192–221.
• 11. Maresso AW, Schneewind O. Sortase as a target of anti-infective therapy. Pharmacol Rev 2008; 60: 128–141.
• 12. Lina G, Piemont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, Vandenesch F, Etienne J. Involvement of Panton–Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29: 1128–1132.
• 13. Karahan ZC, Dolapçı İ, Tekeli A. Influence of reaction optimization on the results of PCR amplification of Panton- Valentine leukocidin genes among Staphylococcus aureus isolates. Mikrobiyol Bül 2009; 43: 519–528.
• 14. Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol 2005; 3: 948–958.
• 15. Kaneko J, Kamio Y. Bacterial two-component and hetero- heptameric pore-forming cytolytic toxins: structures pore- forming mechanism organization of the genes. Biosci Biotechnol Biochem 2004; 68: 981–1003.
• 16. Menestrina G, Dalla Serra M, Prévost G. Mode of action of β-barrel pore-forming toxins of the staphylococcal α-hemolysin family. Toxicon 2001; 39: 1661–1672.
• 17. Lina G, Bohach GA, Nair SP, Hiramatsu K, Jouvin-Marche E, Mariuzza R. Standard nomenclature for the superantigens expressed by Staphylococcus. J Infect Dis 2004; 189: 2334– 2336.
• 18. Holtfreter S, Bröker BM. Staphylococcal superantigens: do they play a role in sepsis? Arch Immunol Ther Exp (Warsz) 2005; 53: 13–27.
• 19. Melish ME, Glasgow LA. The staphylococcal scalded skin syndrome. N Engl J Med 1970; 282: 1114–1119.
• 20. Morlock BA, Spero L, Johnson AD. Mitogenic activity of staphylococcal exfoliative toxin. Infect Immun 1980; 30: 381– 384.
• 21. Rooijakkers SHM, Ruyken M, Roos A, Daha MR, Presanis JS, Sim RB, van Wamel WJ, van Kessel KP, van Strijp JA. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat Immunol 2005; 6: 920–927.
• 22. De Haas CJC, Veldkamp KE, Peschel A, Weerkamp F, Van Wamel WJ, Heezius EC, Poppelier MJ, Van Kessel KP, van Strijp JA.  Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J Exp Med 2004; 199: 687–695.
• 23. Prat C, Bestebroer J, De Haas CJC, Van Strijp JA, Van Kessel KP. A new staphylococcal anti-inflammatory protein that antagonizes the formyl peptide receptor-like 1. J Immunol 2006; 177: 8017–8026.
• 24. Chavakis T, Hussain M, Kanse SM, Peters G, Bretzel RG, Flock JI, Herrmann M,  Preissner KT. Staphylococcus aureus extracellular adherence protein serves as antiinflammatory factor by inhibiting the recruitment of host leukocytes. Nat Med 2002; 8: 687–693.
• 25. Bokarewa MI, Jin T, Tarkowski A. Staphylococcus aureus: staphylokinase. Int J Biochem Cell Biol 2006; 38: 504–509.
• 26. Lee LYL, Liang X, Höök M, Brown EL. Identification and characterization of the C3 binding domain of the Staphylococcus aureus extracellular fibrinogen-binding protein (Efb). J Biol Chem 2004; 279: 50710–50716.
• 27. Lee LYL, Höök M, Haviland D, Wetsel RA, Yonter EO, Syribeys P, Vernachio J, Brown EL. Inhibition of complement activation by a secreted Staphylococcus aureus protein. J Infect Dis 2004; 190: 571–579.
• 28. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Nineteenth Informational Supplements. CLSI Document M 100- S19 (ISBN 1-56238-690-5). Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2012.
• 29. Gilot P, Lina G, Cochard T, Poutrel B. Analysis of the genetic variability of genes encoding the RNA III-activating components Agr and TRAP in a population of Staphylococcus aureus strains isolated from cows with mastitis. J Clin Microbiol 2002; 40: 4060–4067.
• 30. Monday SR, Bohach GA. Use of multiplex PCR to detect classical and newly described pyrogenic toxin genes in staphylococcal isolates. J Clin Microbiol 1999; 37: 3411–3414.
• 31. Ghoreschi K, Mrowietz U, Röcken M. A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J Mol Med 2003; 81: 471–480.
• 32. Projan S, Novick R. The Molecular Basis of Virulence. In: Crossley KB, Archer GL, editors. The Staphylococci in Human Disease. New York, NY, USA: Churchill Livingstone; 1997. pp 55–81.
• 33. Sutherland J, Varnam A. Enterotoxin producing Staphylococcus, Shigella, Yersinia, Vibrio, Aeromonas and Plesiomonas. In: Blackburn CW, McClure PJ, editors. Foodborne Pathogens. Washington, DC, USA: CRC Press; 2002. pp 384–415.
• 34. Lee PK, Vercellotti GM, Deringer JR, Schlievert PM. Effects of staphylococcal toxic shock syndrome toxin-1 on aortic endothelial cells. J Infect Dis 1991; 164: 711–719.
• 35. Galadari I, Sharif MO, Galadari H. Psoriasis: a fresh look. Clin Dermatol 2005; 23: 491–502.
• 36. Chan PF, Foster SJ. Role of SarA in virulence determinant production and environmental signal transduction in Staphylococcus aureus. J Bacteriol 1998; 180: 6232–6241.
• 37. Balcı DD, Duran N, Ozer B, Güneşaçar R, Önlen Y, Yenin JZ. High prevalence of Staphylococcus aureus cultivation and superantigen production in patients with psoriasis. Eur J Dermatol 2009; 19: 238–242.
• 38. Marples RR, Heaton CL, Kligman AM. Staphylococcus aureus in psoriasis. Arch Dermatol 1973; 107: 568–570.
• 39. Tomi NS, Kränke B, Aberer E. Staphylococcal toxins in patients with psoriasis, atopic dermatitis, and erythroderma, and in healthy control subjects. J Am Acad Dermatol 2005; 53: 67–72.
• 40. Sayama K, Midorikawa K, Hanakawa Y, Sugai M, Hashimoto K. Superantigen production by Staphylococcus aureus in psoriasis. Dermatology 1998; 196: 194–198.
• 41. Jassim HA, Bakir SS, Alhamdi KI, Albadran AE. Polymerase chain reaction (PCR) for detection superantigenicity of Staphylococcus aureus isolated from psoriatic patients. Int J Microbiol Res Rev 2013; 1: 22–27.